ClinConnect ClinConnect Logo
Search / Trial NCT06884202

Evaluation of Delefilcon A Contact Lenses

Launched by ALCON RESEARCH · Mar 13, 2025

Trial Information

Current as of July 21, 2025

Recruiting

Keywords

Contact Lenses

ClinConnect Summary

This clinical trial is testing a new type of contact lens called delefilcon A, specifically looking at how well these lenses fit people with refractive errors, such as myopia (nearsightedness). The study will evaluate lenses with different shapes and sizes to see which ones provide the best comfort and vision.

To participate in this trial, you need to be someone who currently wears soft contact lenses for at least six hours a day, five days a week, and can wear lenses with specific prescriptions between -2.00 and -4.00 diopters. You'll also need to have good vision with your current lenses. However, if you have any eye infections, have had eye surgery, or have certain eye conditions, you won't be eligible for this study. While the trial is not yet recruiting participants, it aims to gather important information about the fit of these new lenses, so if you qualify, you could help improve contact lens options for others.

Gender

ALL

Eligibility criteria

  • Key Inclusion Criteria:
  • Successful wearer of spherical soft contact lenses in both eyes for a minimum of 5 days per week and a minimum of 6 hours per day during the past 3 months;
  • Able to wear contact lenses within a range of sphere powers from -2.00 and -4.00 diopters (D);
  • Best Corrected Visual Acuity (BCVA) (with manifest refraction) better than or equal to 0.10 logarithm Minimum Angle of Resolution (logMAR ) in each eye.
  • Key Exclusion Criteria:
  • Any anterior segment infection, inflammation, or abnormality or disease (including systemic) that contraindicates contact lens wear, as determined by the investigator;
  • History of refractive surgery or plan to have refractive surgery during the study, or irregular cornea in either eye;
  • Biomicroscopy findings at screening that are moderate (Grade 3) or higher and/or corneal vascularization that is mild (Grade 2) or higher; presence of corneal infiltrates.
  • Other protocol-defined inclusion/exclusion criteria may apply.

About Alcon Research

Alcon Research is a leading global company dedicated to advancing eye care through innovative research and development. As a subsidiary of Novartis, Alcon focuses on the development of cutting-edge products and therapies for vision correction and eye health, including surgical, pharmaceutical, and consumer eye care solutions. With a commitment to enhancing the quality of life for patients worldwide, Alcon Research conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of care. Through collaboration with healthcare professionals and institutions, Alcon remains at the forefront of ophthalmic advancements, driving progress in the field of vision science.

Locations

Warwick, Rhode Island, United States

Los Angeles, California, United States

San Francisco, California, United States

Maitland, Florida, United States

New York, New York, United States

Granville, Ohio, United States

Oakland, California, United States

Powell, Ohio, United States

Apex, North Carolina, United States

Longwood, Florida, United States

Dallas, Georgia, United States

Charlotte, North Carolina, United States

Patients applied

0 patients applied

Trial Officials

Principal Clinical Trial Lead, Vision Care

Study Director

Alcon Research, LLC

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported